Abstract: The instant invention pertains to novel bi- or tricyclic sterically hindered alkoxyamines, their precursors, a process for their preparation and their use as light stabilizers for polymers or coatings, as flame retardants, as peroxide substitutes (rheology modifiers) or carbon radical scavengers.

Abstract: Disclosed is a liquid composition which is intended to be filled in soft capsules and comprises an oil-insoluble ingredient dispersed in an edible oil, a reactive monoglyceride, and a triglycerol fatty acid ester having a monoester content of 50% or more. The liquid composition to be filled in soft capsules does not comprise bees wax but has a dispersion stability of the oil-insoluble ingredient equal to or higher than that of a conventional composition in which bees wax is used.

Abstract: The present invention relates to a pharmaceutical composition for intravascular delivery of a therapeutic agent, such as paclitaxel, rapamycin, or an analog thereof. The composition includes the therapeutic agent and a biocompatible solvent, such as glycofurol. The composition can aid tissue penetration by the therapeutic agent. A catheter assembly that protects the pharmaceutical composition from the surroundings can be used for its intravascular delivery.

Abstract: The present invention relates to a composition for cosmetics including a polyglycerol fatty acid ester, which is an ester of polyglycerol having an average degree of polymerization of 4 to 100 with a fatty acid having 2 to 18 carbon atoms, has a hydroxyl value equal to or less than 15 mgKOH/g, and has a specific gravity at 20° C. of 0.96 to 1.15; a cosmetic which includes the composition for cosmetics; a method for producing an oil-in-water emulsion cosmetic which includes mixing the composition for cosmetics with a hydrophilic solvent and emulsifying; and a two-separate-layer-type cosmetic, which comprises the composition for cosmetics with water, packaged in a transparent or translucent container.

Abstract: The present invention relates to a novel thixotropic oily vehicle comprising between about 0.2% to about 5% (w/w) of a colloidal silica and between about 0.2% to about 5% (w/w) of a hydrophilic polymer in an edible oil. The interaction between the hydrophylic polymer and the colloidal silica in the above concentration ranges confers thixotropy and a low viscosity under shear on the solution. The invention also relates to capsules filled with the above thixotropic solution used as a fill mass.

Abstract: An emulsifying preparation for an oil-soluble component, which is sensorily superior when applied to an aqueous phase, can maintain stability for a long time, and imposes less restriction for formulation or production is provided. The emulsifying preparation of the present invention contains (A) an oil phase component containing an oil-soluble component, (B) an aqueous phase component containing a polyol, and (C) an emulsifier containing polyglycerol fatty acid monoester having an average degree of polymerization of not less than 10, and having an HLB value of not less than 14 and not more than 18 or showing a transmittance of 1 wt % aqueous solution at 600 nm of not less than 80%.

Abstract: The present invention provides compositions, systems, and methods employing materials to reduce or eliminate vapor transfer of an active substance from a target surface to a non-target surface. In certain embodiments, a material is mixed with a liquid, gas, and/or solid comprising an active substance to form a mixture such that the mixture has a lower vapor pressure than the liquid, gas, and/or solid. In some embodiments, the active substance is a herbicide and the target surface is an agricultural field or crop.

Abstract: A water in oil emulsion lip treatment composition comprising at least one non-polar silicone oil, at least one non-polar organic oil, at least one amphiphilic organic emollient oil, at least one water in oil surfactant; and at least one oil in water surfactant.

Abstract: A process for the preparation of a composition intended for the oral administration of active principles with unacceptable taste, which comprises from about 15% to about 30% of organoleptically unpleasant active ingredient (principle) that is mixed with from about 60% to about 80% of an ester of glycerol or of a fatty acid, to which a wax is optionally added and to which a surfactant is added, and in that it is prepared by a spray-cooling process which can produce a particle size of less than 350 ?m.

Abstract: The invention is directed to the use of oil based suspension concentrates containing a) at least one agrochemical active compound which is solid at room temperature, b) at least one penetration enhancer, c) at least one vegetable or mineral or paraffin oil, d) at least one non-ionic surfactant or dispersing agent and/or at least one anionic surfactant or dispersing agent and e) optionally one or more other additives for the reduction of the drift of a spray liquid containing the oil-based suspension concentrate during spray application.

Abstract: A composition containing therapeutic agents and/or breath freshening agents for use in the oral cavity is disclosed. The carrier comprises water-soluble polymers in combination with certain ingredients and provides a therapeutic and/or cosmetic effect. The film is coated and dried utilizing existing coating technology and exhibits instant wettability followed by rapid dissolution/disintegration upon administration in the oral cavity.

Abstract: The present invention provides a topical gel pharmaceutical formulation of insecticide suitable for treating an ectoparasite in a mammal, comprising: a) about 0.1-10% by weight of an insecticide; b) at least about 75% by weight of an organic solvent selected from the group consisting of a lower alkyl alcohol, a ketone, a glycol and a mixture thereof, wherein the organic solvent contains at least about 40% by weight of the lower alkyl alcohol; and c) at least one polymer selected from the group consisting of a cellulosic polymer, acrylates, methacrylates, and polyvinyl pyrrolidone. The present topical formulations encompass a non-flammable solvent for malathion effective in killing head lice. The present gel pharmaceutical formulation preferably contains malathion and optionally contains isopropyl myristate. The present invention further provides a process of preparing as well as a method of treating ectoparasites in a mammal using the same.

Abstract: An absorbent article, such as a catamenial device, having a liquid pervious topsheet, a backsheet joined to the topsheet, and an absorbent core disposed between the topsheet and the backsheet is disclosed. The absorbent article has a lotion composition applied to at least a portion of the outer surface of the topsheet, the lotion composition including a rheology structurant selected from the group consisting of microcrystalline wax, alkyl dimethicone, ethylene glycol dibehenate, ethylene glycol distearate, glycerol tribehenate, glycerol tristearate, and ethylene bisoleamide.

Abstract: Lipid nanoparticles expressing metal ions and methods for using the compositions for magnetic resonance imaging.

Abstract: An ophthalmic solution comprising a polyethoxylated glyceride in the range of 0.001 to about 10 percent by weight and a buffer agent. These solutions impart surprising comfort and wearability to contact lenses. At the same time the solutions provide good preservative capacity and do not increase protein deposit.

Abstract: The invention discloses synergistic combinations extended chain surfactants and co-surfactants, emulsions or microemulsions and cleaning compositions incorporating the same. In certain embodiments a surfactant system is disclosed which includes extended nonionic surfactants, and a linker surfactant. This system forms stable emulsions or microemulsions with oils, including non-trans fats and fatty acids and these emulsions or microemulsions are stable, irreversible and can be created at low temperature. The cleaning compositions may include the surfactant system alone, a stable emulsion or microemulsion with oil and the surfactant system, a pre-spotter or other pre-treatment or soft surface and hard surface cleaning compositions comprising the surfactant combination.

Abstract: Multiparticulate controlled-release selective serotonin reuptake inhibitor (SSRI) formulations for oral administration, which comprise subunits of a SSRI or a pharmaceutically acceptable salt thereof which are not coated with a rate-controlling polymer, are provided. Methods for preparation and use of these formulations are also provided.

Abstract: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-30 fatty alcohol, monoglyceride or the reaction products thereof.

Abstract: Wax compositions derived from metathesized natural oils and amines and methods of making wax compositions from metathesized natural oils and amines are provided. The wax compositions comprise amidated metathesized natural oils formed from a metathesized natural oil and at least one amine. The methods comprise providing an amine and providing a metathesized natural oil. The methods further comprise mixing the amine and the metathesized natural oil in the presence of a basic catalyst or heat, causing a reaction between the amine and metathesized natural oil, therein forming the amidated metathesized natural oil.

Abstract: The invention relates to new self-emulsifying preparations containing (a) 7 to 20% by weight stearyl oligoglycoside, (b) 7 to 20% by weight cetyl oligoglycoside, (c) 0.1 to 3% by weight myristyl oligoglycoside, (d) 0.5 to 7% by weight lauryl oligoglycoside, (e) 4 to 12% by weight cetyl alcohol, (f) 10 to 20% by weight stearyl alcohol, (g) 20 to 30% by weight C16/18 partial glycerides containing 58 to 62% by weight monoglyceride and (h) 20 to 30% by weight C16/18 partial glycerides containing 30 to 45% by weight monoglyceride, with the proviso that the quantities shown add up to 100% by weight with water.

Abstract: The present invention relates to a paclitaxel composition and the preparation methods thereof to solubilize paclitaxel wherein said composition comprises 4 to 90% by weight of at least one selected from the monoglycerides, 0.01 to 90% by weight of at least one oil and 0.01 to 20% by weight of paclitaxel. Also the present invention relates to a paclitaxel composition including emulsifiers and the preparation methods thereof to solubilize paclitaxel wherein said composition comprises 4 to 90% by weight of at least one selected from the monoglycerides, 0.01 to 90% by weight of at least one emulsifier and 0.01 to 20% by weight of paclitaxel. The composition of the present invention is an effective paclitaxel delivery system since the composition solubilizes paclitaxel, does not form aggregates after being dispersed in water, adsorbs well on the intestinal wall, and therefore has high bioavailability.

Abstract: The present invention relates to an emulsion concentrate with content of water-insoluble oil components (A), of hydrophilic non-ionic emulsifiers (B), of lipophilic co-emulsifiers (C), of polyols (D) and water, which comprises less than 50% by weight of water-insoluble oil component (A)—based on the total weight of the concentrate—comprising components (A), (B) and (C) and (D) in a ratio by weight A:B:C:D=1:(0.25-0.6):(0.25-0.6):(0.45-0.65). The invention further relates to the use of these emulsion concentrates, and also to preparations and paper product, non-woven product or textile product for body care and personal cleansing, which comprise water-insoluble oil components (A), hydrophilic non-ionic emulsifiers (B), lipophilic co-emulsifiers (C), and polyols (D) in a ratio by weight A:B:C:D=1:(0.25-0.6):(0.25-0.6):(0.45-0.65).

Abstract: The present invention relates to the use of a solubilizer for enhancing the solubility of an active pharmaceutical ingredient in water. The present invention further relates to a composition comprising a solubilizer and at least one active pharmaceutical ingredient. In both cases the solubilizer is an alkoxylated monoalcohol or a mixture of alkoxylated monoalcohols, where the alkoxylated monoalcohol or, if a mixture of alkoxylated monoalcohols is present, at least one alkoxylated monoalcohol in the mixture comprises at least one oxypropylene unit.

Abstract: Embodiments of the invention include glycerol esters and use of the same for active agent delivery systems and methods. In an embodiment, the invention includes an active agent eluting device including a glycerol ester, an active agent dispersed within the glycerol ester, the active agent eluting device configured to elute the active agent from the glycerol ester in response to degradation of the glycerol ester. In an embodiment, the invention includes a composition including a glycerol ester; an active agent dispersed within the glycerol ester; the active agent eluting device configured to elute the active agent from the glycerol ester in response to degradation of the glycerol ester. Other embodiments are also included herein.

Abstract: The present invention provides a formulation comprising: i) a lipid matrix; ii) at least one thiolated antioxidant; iii) optionally at least one bioactive agent; and iv) optionally at least one chelating agent.

Abstract: The present invention relates to a therapeutic agent formulation in the form of a nano-emulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, in which the oily phase comprises further to the therapeutic agent, at least one amphiphilic lipid and at least one solubilising lipid, and in which the aqueous phase comprises at least one polyalkoxylated cosurfactant. The invention also relates to a preparation method and use of this formulation.

Abstract: Nanocapsule and nanoemulsion particle compositions having improved physical and pharmacological properties are provided. The nanocapsule or nanoemulsion particle composition can comprise a pharmaceutically acceptable liquid oil phase, a surfactant, and optionally a co-surfactant. The liquid oil phase can comprise a monoglyceride, a diglyceride, a triglyceride, a propylene glycol ester, or a propylene glycol diester. In certain embodiments, the nanocapsule or nanoemulsion particle composition can be lyophilized and subsequently re-hydrated without increasing the mean particle size and/or adversely affecting the potency or efficacy of a therapeutic agent (e.g., paclitaxel) present in the nanocapsules or nanoemulsion particles.

Abstract: The present invention provides methods and compositions for delivery of taxanes in stable oil-in-water emulsion. The inventive emulsion formulation includes an oil phase, aqueous and emulsifier phases. The oil portion includes all or substantial amount of taxane, vegetable oil and medium chain triglycerides; aqueous phase includes an emulsion stabilizer; emulsifier phase reduces the surface tension between oil and aqueous phases to produce a stable oil-in-water emulsion. The inventive compositions produce minimal side effects upon administration.

Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.

Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.

Abstract: The present invention relates to long-wearing, non-aqueous based cosmetic compositions, and related dermatological, pharmaceutical or hygiene compositions. The present invention provides a non-aqueous based composition comprising one or a mixture of two or more emulsifiers.

Abstract: A drug carrier characterized by mainly containing a polyethylene-glycol-modified phospholipid and a cationic lipid and containing the polyethylene-glycol-modified phospholipid in a concentration within a specific range. The drug carrier, which is of the in-blood residence type, is characterized by comprising a polyethylene-glycol-modified phospholipid represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: [wherein X represents the following (II) or (III) and n is an integer of 30-150] [wherein R1 represents a saturated linear C17-22 fatty acid residue] and 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglylcerol. It is further characterized in that the polyethylene-glycol-modified phospholipid represented by the general formula (I) is contained in an amount of 30-50 wt. % based on the total amount of the lipids in the drug carrier.

Abstract: Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.

Abstract: The object of the present invention is a method for producing oil-in-water (O/W) emulsions from self-emulsifying gel concentrates without agitation, such as stirring, or in a laminar flow field.

Abstract: The present invention is directed to a gel composition which comprises an specific solid alkyl silicone polymers combined with specific liquid esters selected from the group consisting of glyceryl esters, trimethylolpropane esters, and pentaerythritol esters. The invention is also directed to a process for providing emolliency to the skin by applying the compositions of the present invention. Finally, the invention is also directed to application of sun screen actives, hydroxy acids, antioxidants, flavonoids, tocopherol, vitamins and the like to the skin in gelled form.

Abstract: Self-microemulsifying drug delivery systems and microemulsions used to enhance the solubility of pharmaceutical ingredients comprising a polyoxyethylene sorbitan fatty acid ester emulsifier; a fatty acid ester co-emulsifier and an oil.

Abstract: A composition suitable for the local delivery of cosmetic and/or pharmaceutical agents into the skin containing at least two biocompatible organic solvents, a polar lipid, a surfactant, water, urea and a thickener wherein the organic solvents include an ester and a dihydric and/or polyhydric alcohol is provided.

Abstract: The invention provides mixtures of tri-, di-, and mono-glycerides obtained by esterification of fatty acids from vegetal oils such as olive oil with glycerine, their production process and their use in cosmetic and pharmaceutical preparations, in particular as vehicle or solubiliser for active ingredients.

Abstract: O/W-emulsifiers are described, comprising: (a) 30-50% by weight of hardened palm oil glycerides; (b) 15-35% by weight of potassium cetyl phosphates; (c) 20-30% by weight of cetyl alcohol, and (d) 5-15% by weight of potassium phosphate, in each case with respect to the total mass of the emulsifier. Further described are corresponding O/W-emulsions, comprising an aqueous phase, an oil phase dispersed in the aqueous phase and between 0.25 and 15% by weight of the abovementioned O/W-emulsifier. Finally, also described are methods for manufacturing such an O/W-emulsion.

Abstract: A method for treating diaper rash, leg ulcers and bed sores using super hydrated bacteriostatic topical preparation with a stable acid pH 5.82, by applying this topical application, which is a mixture of anhydrous lanolin (USP), water, boric acid powder (USP), edible corn starch, white petrolatum, cosmetic grade, and zinc oxide ointment (USP 20% zinc oxide) mixed in a paddle mixer at a temperature of about 100° F. to 107° F. then applying topically, the super hydrated bacteriostatic preparation, at room temperature, on the rash, leg ulcers, or bed sores.

Abstract: The present application relates to an oral formulation of amphotericin B and other therapeutic agents, which formulation comprises one or more fatty acid glycerol esters and one or more PEG modified phospholipids or fatty acid esters. The formulation provides enhanced bioavailability and/or increased stability of the therapeutic agent at the low pH found in gastric fluid.

Abstract: Diacyl lipid-polymer conjugates are used to enhance the solubility of lipophilic drugs in aqueous solution. The conjugates comprise a backbone, two lipophilic acyl groups and a hydrophilic polymer.

Abstract: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-30 fatty alcohol, monoglyceride or the reaction products thereof.

Abstract: The present invention relates to a method for preparing nano-emulsions comprising at least one aqueous continuous phase and at least one oily dispersed phase, comprising the steps of: (i) preparing the oily phase comprising at least one amphiphilic lipid and at least one solubilising lipid; (ii) dispersing the oily phase in an aqueous phase under the effect of sufficient shear force to form a nano-emulsion; and (iii) recovering the nano-emulsion thus formed.

Abstract: Pharmaceutical formulations comprising a multi-phasic pharmaceutical composition, and an adsorbent carrier, where the pharmaceutical formulation is a solid dosage form. Methods for preparing such pharmaceutical compositions are described.

Abstract: The present invention relates to a new lyophilized pharmaceutical composition capable of adhering to oral mucosal tissue for an extended period of time for delivering active pharmaceutical ingredient through the oral mucosal tissue using transmucosal absorption.

Abstract: An ophthalmic solution comprising a polyethoxylated glyceride in the range of 0.001 to about 10 percent by weight and a buffer agent. These solutions impart surprising comfort and wearability to contact lenses. At the same time the solutions provide good preservative capacity and do not increase protein deposit.

Abstract: Composition for the implementation of a therapeutic method for the human or animal body, comprising a fatty phase (O) and an aqueous phase (W), in the form of an 5 emulsion of the water-in-oil (W/O) type, in which said aqueous phase (W) comprises at least one hydrosoluble active ingredient, characterized in that said composition has a viscosity, measured at 25° C. in a 250-cm3 beaker having a diameter of about 7 cm, using a Brookfield LVT viscosimeter equipped with a No. 2 spindle turning at a speed of 30 or 60 revolutions pre minute, of less than or equal to 10 [sic] 2000 mPas, and preferably less than 200 mPas.

Abstract: The present invention relates to compositions for transdermal administration of a therapeutic agent for providing a systemic therapeutic effect. In particular, the invention relates to spreadable compositions, or compositions which may be solid at a temperature of about 25° C. or less and have a softening point of not higher than 35° C., wherein transdermal administration of the therapeutic agent may be either rapid or sustained.

Abstract: The present invention relates to compositions for transdermal administration of therapeutic agents for providing a local and sustained therapeutic effect, wherein the extent of systemic administration can be controlled. In particular, the invention relates to spreadable compositions, or compositions which may be solid at a temperature of about 25° C. or less and have a softening point of not higher than 35° C., for use in the treatment of pain and/or inflammation or administration of a local anaesthetic, wherein transdermal administration of the therapeutic agent may be either rapid or sustained.